MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
53.00
+0.18
+0.33%
After Hours: 53.00 0 0.00% 17:50 07/11 EDT
OPEN
52.28
PREV CLOSE
52.83
HIGH
53.77
LOW
52.02
VOLUME
766.14K
TURNOVER
--
52 WEEK HIGH
60.60
52 WEEK LOW
32.50
MARKET CAP
3.29B
P/E (TTM)
69.87
1D
5D
1M
3M
1Y
5Y
1D
Citizens JMP healthcare analysts hold an analyst/industry conference call
TipRanks · 3d ago
Weekly Report: what happened at PTGX last week (0630-0704)?
Weekly Report · 5d ago
Protagonist Therapeutics: Strategic Advancements and Promising Data Drive Buy Rating
TipRanks · 07/02 00:55
Truist Financial Remains a Buy on Protagonist Therapeutics (PTGX)
TipRanks · 07/01 11:15
Strategic Entry and Innovation: Protagonist Therapeutics’ Potential in the Obesity Market with PN-477
TipRanks · 07/01 11:06
Protagonist Therapeutics: Promising Developments in Obesity Treatment with PN-477 and Strategic Growth Opportunities
TipRanks · 07/01 10:55
Protagonist Therapeutics: Promising Obesity Program and Strategic Partnerships Drive Buy Rating
TipRanks · 07/01 10:45
H.C. Wainwright Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)
TipRanks · 07/01 10:37
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.